Zomedica Posts Record $9.9M Q3 Revenue, Cuts Net Loss 48%
ZOMDF sits 31% above its 52-week low of $0.07.
Summary
Zomedica reported record third-quarter revenue of $9.9 million, up 22% year-over-year, its second straight quarter above $9 million. Net loss fell to $3.2 million from $6.1 million a year ago, a 48% reduction, as operating expenses dropped 21% ($2.5 million) and cash burn improved 32% to $3.2 million. Diagnostics revenue jumped 113% on the Boehringer Ingelheim collaboration and international expansion, while core commercial revenue excluding Development Services grew 18%. The company ended the quarter with $40.9 million in liquidity against a micro-cap valuation, so the balance sheet remains the dominant part of the story. Watch the November 20 webinar for management commentary on closing the year.
At the time of this announcement, ZOMDF was trading at $0.09 on OTC in the Life Sciences sector, with a market capitalization of approximately $90.2M. The 52-week trading range was $0.07 to $0.16. This news item was assessed with positive market sentiment and an importance score of 7 out of 10. Source: ACCESS Newswire.